Related Experiment Video
Updated: Jun 4, 2026

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Published on: August 9, 2022
Cardiotoxicity adverse outcome pathway network: towards mechanistic and quantitative modelling
Luiz Ladeira1, Devon A Barnes2, Rosalinde Masereeuw2
1Biomechanics Research Unit, GIGA Institute, University of Liège, Liège, Belgium.
Introduction:
Chemical-induced heart toxicity remains a major challenge in drug development and environmental safety, largely because current testing often relies on narrow, late-stage endpoints that miss the complex biological progression of the toxicities. To address this, we developed a comprehensive Adverse Outcome Pathway (AOP) network that maps how early (bio) chemical triggers evolve into organ-level dysfunction.
Methods:
By integrating data from the OECD AOP-Wiki, we constructed a unified network of 64 biological events and 94 documented relationships that identifies the critical biological "crossroads" where different toxic chemicals converge to cause heart damage.
Results/Discussion:
Our analysis reveals a compact core of central biological events, such as oxidative stress and mitochondrial dysfunction, which act as the primary drivers of cardiac injury. This network approach moves beyond single, linear pathways to show how systemic factors, including interactions with other organs like the kidneys, contribute to cardiotoxicity. To translate these findings into a practical resource for the broader scientific community, we developed a methods catalogue that links these biological events to specific laboratory assays. To ensure this work is accessible and actionable, we hosted the network on an interactive, FAIRaligned web platform. By providing a clear scaffold for understanding heart safety, this resource enables the design of more human-relevant, animal-free testing strategies and helps prioritise the most impactful biomarkers for future safety assessments.
Insights
A new Adverse Outcome Pathway (AOP) network reveals key biological events driving chemical-induced heart toxicity. This resource aids in developing advanced, animal-free safety testing strategies for drug development and environmental assessment.
Area of Science:
- Toxicology
- Biomedical Science
- Environmental Health
Background:
- Chemical-induced heart toxicity poses significant challenges in drug development and environmental safety.
- Current testing methods often fail to capture the complex biological progression of toxicities due to narrow, late-stage endpoints.
Purpose of the Study:
- To develop a comprehensive Adverse Outcome Pathway (AOP) network to map the progression of chemical-induced heart toxicity.
- To identify critical biological pathways and biomarkers for improved cardiotoxicity assessment.
- To create a practical, accessible resource for designing human-relevant, animal-free testing strategies.
Main Methods:
- Integrated data from the OECD AOP-Wiki to construct a network of 64 biological events and 94 relationships.
- Identified central biological events and 'crossroads' where different toxic chemicals converge.
- Developed a methods catalogue linking biological events to laboratory assays.
- Hosted the network on an interactive, FAIR-aligned web platform.
Main Results:
- Revealed a core set of biological events, including oxidative stress and mitochondrial dysfunction, as primary drivers of cardiac injury.
- Demonstrated how systemic factors and inter-organ interactions (e.g., with kidneys) contribute to cardiotoxicity.
- Established a network that moves beyond linear pathways to illustrate complex toxicological interactions.
Conclusions:
- The developed AOP network provides a clear scaffold for understanding heart safety.
- This resource facilitates the design of more human-relevant, animal-free testing strategies.
- Enables prioritization of impactful biomarkers for future safety assessments, enhancing drug development and environmental safety evaluations.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Models: Overview
Pharmacodynamic Models: Linear Concentration–Effect Model
Mechanistic Models: Overview of Compartment Models
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
